DEERFIELD MANAGEMENT COMPANY, L.P. 3
3 · Parabilis Medicines, Inc. · Filed Jun 9, 2026
Insider Transaction Report
Form 3
Flynn James E
10% OwnerOther
Holdings
- (indirect: Through Deerfield Private Design Fund III, L.P.)
Series A Preferred Stock
[F1][F5][F6]→ Voting Common Stock (122,990 underlying) - (indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Series A Preferred Stock
[F1][F5][F6]→ Voting Common Stock (122,990 underlying) - (indirect: Through Deerfield Private Design Fund III, L.P.)
Series B Preferred Stock
[F2][F5][F6]→ Voting Common Stock (149,238 underlying) - (indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Series B Preferred Stock
[F2][F5][F6]→ Voting Common Stock (149,238 underlying) - (indirect: Through Deerfield Private Design Fund III, L.P.)
Series C Preferred Stock
[F3][F5][F6]→ Voting Common Stock (260,992 underlying) - (indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Series C Preferred Stock
[F3][F5][F6]→ Voting Common Stock (260,992 underlying) - (indirect: Through Deerfield Private Design Fund III, L.P.)
Series D Preferred Stock
[F4][F5][F6]→ Voting Common Stock (407,132 underlying) - (indirect: Through Deerfield Healthcare Innovations Fund, L.P.)
Series D Preferred Stock
[F4][F5][F6]→ Voting Common Stock (407,132 underlying)
Footnotes (6)
- [F1]Each share of Series A Preferred Stock is convertible into approximately 0.7406 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock.
- [F2]Each share of Series B Preferred Stock is convertible into approximately 1.0389 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock.
- [F3]Each share of Series C Preferred Stock is convertible into approximately 1.0578 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock.
- [F4]Each share of Series D Preferred Stock is convertible into approximately 0.8764 shares of the Issuer's voting common stock (on an adjusted basis after giving effect to the 1-for-1.5389 reverse split of the Issuer's common stock effected by the Issuer on June 3, 2026) and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock.
- [F5]This Form 3 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ("Fund III"). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ("Deerfield Innovations" and together with Fund III, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P. and Deerfield Management Company, L.P
- [F6]In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Signature
/s/ Jonathan Isler, Attorney-in-Fact|2026-06-09